TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02487966

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mirror Therapy: Sham
Description: Subjects will be asked to perform movements (15 minutes daily) using the unaffected limb while watching its mirrored reflection superimposed over the affected limb, only the mirror will be covered. During Mirror Therapy, subjects will be asked to consciously relate the movement observed in the mirror to their phantom limb and to keep their attention focused on the task. Instructions will be explained verbally, demonstrated by a therapist, and performed by the subject in front of the therapist. We will use the same all of these techniques as active Mirror Therapy only the mirror will be covered during all activities.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Mirror Therapy: Sham
Description: Subjects will be asked to perform movements (15 minutes daily) using the unaffected limb while watching its mirrored reflection superimposed over the affected limb, only the mirror will be covered. During Mirror Therapy, subjects will be asked to consciously relate the movement observed in the mirror to their phantom limb and to keep their attention focused on the task. Instructions will be explained verbally, demonstrated by a therapist, and performed by the subject in front of the therapist. We will use the same all of these techniques as active Mirror Therapy only the mirror will be covered during all activities.
Study: NCT05046626

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional counseling
Description: Intervention based on nutritional counseling under Cognitive Behavioral Theory and the used of strategies like self-monitoring, goals, cognitive restructuring and social support.
Study: NCT01951898

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast
Description: 10mg/day, once a daily after dinner, for 28dyas

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Montelukast
Description: 10mg/day, once a daily after dinner, for 28dyas
Study: NCT00222742

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: induced moderate hypothermia
Description: Subjects assigned to the treatment arm will be cooled to 32-33 °C for 48 hours and then slowly warmed.
Study: NCT03400241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium Bromide Monohydrate
Description: Tiotropium Easyhaler 10 mcg/dose Product A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium Bromide Monohydrate
Description: Tiotropium Easyhaler 10 mcg/dose Product B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium Bromide Monohydrate
Description: Tiotropium Easyhaler 10 mcg/dose Product C

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium Bromide Monohydrate
Description: Spiriva 18 Mcg/capsule inhaled via HandiHaler
Study: NCT03314935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB001158
Description: Phase 1: INCB001158 administered orally twice daily at the protocol-defined dose. Phase 2: INCB001158 administered orally twice daily at the recommended dose from Phase 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB001158
Description: Phase 1: INCB001158 administered orally twice daily at the protocol-defined dose. Phase 2: INCB001158 administered orally twice daily at the recommended dose from Phase 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB001158
Description: Phase 1: INCB001158 administered orally twice daily at the protocol-defined dose. Phase 2: INCB001158 administered orally twice daily at the recommended dose from Phase 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin administered intravenously at the protocol-defined dose and schedule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Leucovorin at the protocol-defined dose and regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 5-Fluorouracil at the protocol-defined dose and regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine at the protocol-defined dose and regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin at the protocol-defined dose and regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel at the protocol-defined dose and regimen.
Study: NCT00869167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon
Description: melatonin agonist

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ramelteon
Description: melatonin agonist
Study: NCT02043990

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Noninvasive NAVA ventilation
Description: Noninvasive NAVA Ventilation versus conventional noninvasive Pressure Support Ventilation
Study: NCT00366210

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Constraint-Induced Movement (CI) Therapy
Study: NCT00877006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bendamustine
Study: NCT00366210

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Stretching, Relaxation, & Biofeedback
Description: Passive stretching of both arms, EMG biofeedback for more-impaired arm
Study: NCT04906031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium stibogluconate
Description: Sodium stibogluconate 900 mg/m2/day will be given on d1-5 and d15-19. 28 days per cycle.
Study: NCT01117194

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rehabilitation Robot for Upper Limb Dysfunction (NTUH Model One)
Description: Use an intelligent robot to assist upper limb rehabilitation.
Study: NCT01196013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: Intravenous, 30 mg/m2, 52 mg/m2
Study: NCT03576261

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preoperative colloid fluid bolus (Gelofusine)
Description: Preoperative colloid fluid bolus

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Preoperative transthoracic echocardiography
Description: Screening of biventricular systolic and diastolic function of the heart and level of venous return by transthoracic echocardiography approximately one hour before preoperative fluid therapy and anesthesia induction.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Preoperative transthoracic echocardiography
Description: Screening of biventricular systolic and diastolic function of the heart and level of venous return by transthoracic echocardiography approximately one hour before preoperative fluid therapy and anesthesia induction.
Study: NCT00932074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KP-413 Ointment
Description: Study drug ointment to be applied topically to the selected treatment areas on the head/neck and torso/limbs twice a day for 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KP-413 Ointment
Description: Study drug ointment to be applied topically to the selected treatment areas on the head/neck and torso/limbs twice a day for 4 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: KP-413 Ointment
Description: Study drug ointment to be applied topically to the selected treatment areas on the head/neck and torso/limbs twice a day for 4 weeks.
Study: NCT00974155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram, venlafaxine, lithium
Description: oral application, highest tolerable dose, once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram, venlafaxine
Description: oral application, highest tolerable dose, once daily
Study: NCT00877006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rituximab
Study: NCT04268069

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PL9643 Ophthalmic Solution
Description: PL9643 Ophthalmic Solution as topical ophthalmic drops administered bilaterally for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Ophthalmic Solution
Description: Placebo solution as topical ophthalmic drops administered bilaterally for 12 weeks.
Study: NCT03308682

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-DOTA-EB-TATE
Description: The patients were intravenously injected with single dose 0.50GBq-0.70GBq (13.5-18.9 mCi) of 177Lu-DOTA-EB-TATE and monitored at 2, 24, 72, 120 and 168 hours post-injection.
Study: NCT04410159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povidone-Iodine
Description: Gargle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Essential oils
Description: Gargle

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tap water
Description: Gargle
Study: NCT00891696

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rapamycin
Description: Single 16-mg oral dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rapamycin
Description: Single 16-mg oral dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rapamycin
Description: Single 16-mg oral dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rapamycin
Description: Single 16-mg oral dose

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Amino acid supplementation
Description: Nutritional drink containing essential amino acids
Study: NCT00877006

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vincristine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Study: NCT00891696

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Amino acid supplementation
Description: Nutritional drink containing essential amino acids

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Amino acid supplementation
Description: Nutritional drink containing essential amino acids
Study: NCT00877006

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin
Study: NCT00489372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Se-methyl-seleno-L-cysteine
Description: Given orally

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01121003

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: weight maintenance, low sugar diet

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: weight maintenance, high fructose diet

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: weight maintenance, high fructose diet+ exercise
Study: NCT03288324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Description: Tofacitinib 5 mg twice daily
Study: NCT03483766

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic Functional Rehabilitation system
Description: The tailored-made EMG driven soft-robotic hand prosthesis for tetraplegia individuals may help to preserve the residual function and to enhance the functional recovery.
Study: NCT02027922

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fluor Protector S
Description: Fluor Protector S intervention group A (25 ml) Duraphat group B (25ml)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fluor Protector S
Description: Fluor Protector S intervention group A (25 ml) Duraphat group B (25ml)
Study: NCT03036449

Intervention type: BEHAVIORAL
Intervention: Education program for NICU caregivers.
Description: Intervention includes a main initial educational program, maintenance education programs and tools supply~- Main educational program will include 9 hours of courses into NICU (1 hour each week) and @ learning modules validation.~Topics: Main causes of medication errors, How to analyse retrospectively medication errors, Strategies to reduce medication errors, How to improve communication between health professional; Task interruption; Standardisation of preparation.....~* Maintenance education program will return on specific topics of main program and will be fitted to each NICU needs.~* Examples of Tools: check lists, medication neonatal formulary, Sound alike and Look alike drug lists...

Intervention type: BEHAVIORAL
Intervention: Education program for NICU caregivers.
Description: Intervention includes a main initial educational program, maintenance education programs and tools supply~- Main educational program will include 9 hours of courses into NICU (1 hour each week) and @ learning modules validation.~Topics: Main causes of medication errors, How to analyse retrospectively medication errors, Strategies to reduce medication errors, How to improve communication between health professional; Task interruption; Standardisation of preparation.....~* Maintenance education program will return on specific topics of main program and will be fitted to each NICU needs.~* Examples of Tools: check lists, medication neonatal formulary, Sound alike and Look alike drug lists...

Intervention type: BEHAVIORAL
Intervention: Education program for NICU caregivers.
Description: Intervention includes a main initial educational program, maintenance education programs and tools supply~- Main educational program will include 9 hours of courses into NICU (1 hour each week) and @ learning modules validation.~Topics: Main causes of medication errors, How to analyse retrospectively medication errors, Strategies to reduce medication errors, How to improve communication between health professional; Task interruption; Standardisation of preparation.....~* Maintenance education program will return on specific topics of main program and will be fitted to each NICU needs.~* Examples of Tools: check lists, medication neonatal formulary, Sound alike and Look alike drug lists...
Study: NCT02713789

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hMaxi-K Single Treatment/ 2 escalating dose levels (8000 µg and 16000 µg injection)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (PBS-20% sucrose)
Study: NCT00891696

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Amino acid supplementation
Description: Nutritional drink containing essential amino acids

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Low-intensity resistance exercise
Description: Leg extension exercises on a Cybex leg extension machine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Low-intensity resistance exercise
Description: Leg extension exercises on a Cybex leg extension machine

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low-intensity resistance exercise
Description: Leg extension exercises on a Cybex leg extension machine

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low-intensity resistance exercise
Description: Leg extension exercises on a Cybex leg extension machine

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low-intensity resistance exercise
Description: Leg extension exercises on a Cybex leg extension machine

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low-intensity resistance exercise
Description: Leg extension exercises on a Cybex leg extension machine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium nitroprusside
Description: Variable rate for 3 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium nitroprusside
Description: Variable rate for 3 hours
Study: NCT03129412

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radical radiotherapy
Description: radical radiotherapy for primary tumors were given. Appropriate treatments for olio-metastatic lesions will be assigned to those who got PR,SD after chemotherapy.
Study: NCT00891163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Synera™ Topical Patch (70 mg lidocaine/70 mg tetracaine)
Description: 30 minute applicable on antecubital fossa

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Patch
Description: placebo
Study: NCT01921634

Intervention type: OTHER
Group type: OTHER
Intervention: Modified Pathologic Analysis

Intervention type: OTHER
Group type: OTHER
Intervention: Modified Pathologic Analysis
Study: NCT04186728

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Magnesium glycinate
Description: Daily magnesium capsule.
Study: NCT00891696

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Blood flow restriction cuff
Description: Blood flow restriction for 5 minutes after the second biopsy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Blood flow restriction cuff
Description: Blood flow restriction for 5 minutes after the second biopsy
Study: NCT04186728

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Magnesium glycinate
Description: Daily magnesium capsule.
Study: NCT04066530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-203
Description: AD-203 administered two times daily for two weeks
Study: NCT00891696

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Blood flow restriction cuff
Description: Blood flow restriction for 5 minutes after the second biopsy

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Low-intensity resistance exercise
Description: Leg extension exercises on a Cybex leg extension machine
Study: NCT04066530

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mucosta tab.
Description: Mucosta tab. administered three times daily for two weeks
Study: NCT00891696

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low-intensity resistance exercise
Description: Leg extension exercises on a Cybex leg extension machine

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low-intensity resistance exercise
Description: Leg extension exercises on a Cybex leg extension machine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Low-intensity resistance exercise
Description: Leg extension exercises on a Cybex leg extension machine
Study: NCT01770743

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AV7909
Description: Anthrax Vaccine Adsorbed plus CPG 7909 Adjuvant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AV7909
Description: Anthrax Vaccine Adsorbed plus CPG 7909 Adjuvant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AV7909
Description: Anthrax Vaccine Adsorbed plus CPG 7909 Adjuvant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AV7909
Description: Anthrax Vaccine Adsorbed plus CPG 7909 Adjuvant

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BioThrax
Study: NCT01366573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1521498
Description: GSK1521498 20 mg administered with alcohol to determine PK/PD interactions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1521498
Description: GSK1521498 20 mg administered with alcohol to determine PK/PD interactions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03810846

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking football exercise program
Description: Participants will be organized in two teams of 20 players. Each team will have 60-min walking football exercise sessions three times per week (non-consecutive days), during three months (36 sessions). Different walking football exercise strategies will be developed according to participants' motor skills and tested with dose-escalated intensity for its safety and enjoyment. Exercise intensity will range between light to vigorous. No submaximal or maximal exercises will be tested. Exercise sessions will be conducted on a sports hall (indoor court) by a football coach and supervised by an exercise physiologist and a nurse.
Study: NCT02073162

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Major Abdominal Surgery
Description: •All types of open or lap-assisted abdominal or pelvic surgery with an expected duration of at least 2 hours, and an expected hospital stay of at least 3 days (for example, oesophagectomy, gastrectomy, pancreatectomy, colectomy, aortic or aorto-femoral vascular surgery, nephrectomy, cystectomy, open prostatectomy, radical hysterectomy, and abdominal incisional hernia repair)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Major Abdominal Surgery
Description: •All types of open or lap-assisted abdominal or pelvic surgery with an expected duration of at least 2 hours, and an expected hospital stay of at least 3 days (for example, oesophagectomy, gastrectomy, pancreatectomy, colectomy, aortic or aorto-femoral vascular surgery, nephrectomy, cystectomy, open prostatectomy, radical hysterectomy, and abdominal incisional hernia repair)
Study: NCT01658085

Intervention type: DEVICE
Intervention: ACE14S
Description: Total thyroidectomy (total bilateral extracapsular lobectomy) for Multinodular Goiter with ACE14S

Intervention type: DEVICE
Intervention: HARMONIC FOCUS®
Description: Total thyroidectomy (total bilateral extracapsular lobectomy) for Multinodular Goiter with HARMONIC FOCUS®
Study: NCT03115372

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Attend CRC education session

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Intervention
Description: Attend healthy nutrition session

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Informational Intervention
Description: Receive CRC screening brochure

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-Based Intervention
Description: Receive telephone reminder about CRC screening

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telephone-Based Intervention
Description: Receive telephone reminder about healthy nutrition
Study: NCT03404635

Intervention type: DRUG
Intervention: Apixaban
Description: Apixaban as standard of care for VTE
Study: NCT01816425

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermoplastic partial denture

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CoCr partial denture
Study: NCT04186728

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Daily placebo capsule.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily placebo capsule.
Study: NCT03404635

Intervention type: DRUG
Intervention: Rivaroxaban
Description: Rivaroxaban as standard of care for VTE